Michael P. Murphy, MD

Associate Professor of Surgery
Associate Professor of Cellular and Integrative Physiology Clinical
Director, Vascular and Cardiac Center for Adult Stem Cell Therapy
Director, IU Center for Aortic Disease

Specialty: Vascular Surgery
Medical School: Columbia University
Residency: Brigham and Women's Hospital, Harvard Medical School
Fellowship: Duke University (Vascular Surgery)


Dr. Murphy is a native of New York and received his medical degree from the College of Physicians and Surgeons of Columbia University where he was selected for Alpha Omega Alpha honor medical society during his junior year. Dr. Murphy completed his general surgery training at the Brigham and Women’s Hospital, Harvard Medical School where he was chosen for the Francis Daniels Moore Senior Resident Award. During his residency he spent two years in research in the cardiac surgery laboratory at the Harvard Medical School studying heart failure and skeletal muscle augmentation of ventricular function. Dr. Murphy continued on as faculty as the Assistant to the Surgeon in Chief at the Brigham and Women’s Hospital and Instructor in Surgery at Harvard Medical School before continuing his fellowship training in vascular surgery at Duke University Medical Center. Dr. Murphy joined the faculty of the Indiana University School of Medicine in 2005 where he serves as Associate Professor of Surgery and Cellular and Integrative Physiology (tenured in research), Clinical Director for the Vascular and Cardiac Adult Stem Cell Therapy Center, Director of the IU Center for Aortic Disease, and Executive Committee of the Cardiovascular Cell Therapy Research Network for the National Heart, Lung, and Blood Institute.


Dr. Murphy’s interest is in stem cell physiology and he designed and conducted the first clinical trial in the U.S. using autologous bone marrow cells for peripheral arterial disease in 2003. Dr. Murphy has multiple grants from the National Institutes of Health, the Veterans Administration, and the Strategic Research Initiatives including a $63 million program grant (NIH 1UM1HL113457-01) that is focusing on clinical research in stem cell therapies for cardiovascular disease. Dr. Murphy has authored over sixty publications and is currently the national Principal Investigator on four stem cell trials in arterial and aortic disease. He serves as Director of the IU Health Center for Aortic Disease and Clinical Director the Vascular and Cardiac Adult Stem Cell Therapy Center.


Dr. Murphy belongs to the American Medical Association, American College of Surgeons, American Heart Association, International Society for Stem Cell Research, North American Vascular Biology Organization, American Society of Gene and Cell Therapy, International Society for Stem Cell Research, Society for Vascular Surgery, and Association for Academic Surgery.


Dr. Murphy joined the U.S. Army Reserve in 2004 and served two tours in Iraq as a vascular and trauma surgeon, receiving the Army Commendation Medal, Meritorious Service Medal, and Bronze Star for his service. He now resides in Carmel, Indiana with his wife, Laura, and their family.


Riley Physicians
IU Health Physicians


IU Health Methodist/IU Health University
IU Health North
IU Health Saxony

Location Information

Richard L. Roudebush VA Hospital

1481 W. 10th St.

Indianapolis, IN 46202

IU Health Multi-Specialty Clinic

1801 N. Senate Blvd., Ste 3500

Indianapolis, IN 46202

Clinical Interests


Accepting New Patients

Schedule an Appointment  Clinical Trials

Current Funding.

Veterans Equitable Research Allocation. The Richard Roudebush Veterans Administration Medical Center. Support to develop translational programs emphasizing the genetic, molecular, and cellular mechanisms in the pathogenesis of aneurysmal degeneration of the aorta and novel therapies for treatment. $1.1 M. Murphy, PI.


Strategic Research Initiatives Grant. The IU Health Center for Aortic Disease. Institutional program grant. $1.0M. Murphy, PI.


NIH 1UM1HL113457-01 .Utility of Autologous and Allogeneic Cell Therapy for Peripheral Arterial Disease. Cardiovascular  Cell Therapy Research Network of the National Heart, Lung, and Blood Institute. (7 year program grant)  $63M, Principal Investigator.

Indiana University  Collaborative Research Grant. Placenta Stem Cell-Based Tissue Engineering of the Trachea: Airway Management of the Future. $70,000. Murphy, 


Clinical Research.

Cell Therapy for Vascular Disease.  Dr. Murphy is the national PI for the multicenter, double blinded, randomized control Phase III MarrowStim Trial, sponsored by Biomet, Inc. (Warsaw, IN). This pivotal trial is designed to determine if autologous bone marrow cells prevent amputation in patients with critical limb ischemia (CLI) with no options for revascularization. Dr. Murphy is the lead PI in a single center Phase I trial, Tissue Genesis® Icellator Cell Isolation System™ for Autologous Adipose-Derived Stromal Vascular Fraction Cells to Treat Critical Limb Ischemia (TGAIT) which  is the first PAD trial to use adipose derived progenitor cells. In addition Dr. Murphy has designed and is leading the Stem Cell Therapy to Prevent Expansion of Abdominal Aortic Aneurysms (STOP-AAA) and the Clinical and Histological Analysis of Mesenchymal Progenitor Cells in Patients Undergoing Amputation (CHAMP) Trial funded through the National Institutes of Health.


The Indiana University Center for Aortic Disease. This is a multidisciplinary effort directed by Dr. Murphy that includes the IU School of Medicine, the main campus in Bloomington, and Purdue University and consists of clinicians and scientists from cardiology, cardiothoracic and vascular surgery, molecular biology, and genetics. The objectives of this program are to develop new and expand existing programs in basic science, translational, and clinical research focusing on the pathogenesis and treatment of aortic disease. The current lines of investigation include delineation of the genetic, molecular and cellular events leading to AAA formation, identifying targets in these pathways for novel microRNA and stem cell therapies, creation of an aortic  tissue and gene bank, and a database to track outcomes after surgical interventions.


Basic Science.

Immunomodulatory and Reparative Properties of Human Placenta Derived Stem Cells. We have previously isolated and characterized a unique population of mesenchymal stromal cells (MSCs) from the chorionic villi of human term placenta that are derived from the maternal endometrium. These MSCs have demonstrated profound immunosuppressive properties and pluriotency in vitro and in vivo. We are currently testing these cells in animal models on intimal hyperplasia, aortic aneurysm, and atherosclerosis.


Mesenchymal Stem Cell Modulation of Aortic Inflammation in the Pathogenesis of Aneurysm Formation. Our laboratory is focusing in the utility of human MSCs from adipose tissue, bone marrow, and placenta in suppressing aneurysm formation in mice, specifically focusing on CD4+ and CD8+CD25- T cell suppression, induction of CD4+CD25+ Foxp3+ T regulatory cells, polarization of macrophages from the M1 to M2 phenotype, and the role of TNF-α stimulated protein 6 and CD44 in mediating MSC immune modulation. We are also comparing different routes of cell delivery and escalating dose parameters.


The Role of Endothelial Colony Forming Cells in Vascular Homeostasis and Atherosclerosis. Expanding upon the plenary work at IU in the first descriptions of a true endothelial progenitor cell, the endothelial colony forming cell (ECFC), we have isolated and characterized ECFCs from human arteries and veins. We have further demonstrated the ECFCs from atherosclerotic arteries exhibit evidence of clonal exhaustion due to replicative stress to maintain an intact and functional endothelium. We are now  investigating the  different pathways that mediate ECFC senescence in diabetes  and advanced age, two distinctly different stressors that induce ECFC apoptosis.

  1. Miller SJ, Norton LE, Murphy MP, Dalsing MC, Unthank JL. The role of the renin-angiotensin system  and oxidative stress in spontaneously hypertensive rat  mesenteric collateral growth impairment. Am J Physiol Heart Circ Physiol.2007;292: H2523-H2531.
  2. Murphy MP, Wang H, Patel AN,  Kambhampati S, Angle N,Chan K, Marleau AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH. Allogeneic endometrial regenerative cells: an "off the shelf" solution for critical limb ischemia? Journal of Translational Medicine 2008.
  3. Zhang Y, Ingram DA, Murphy MP, Saadatzadeh MR, Mead LR, Prater DN, Rehman J. Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2009;296: H103-111.
  4. Distasi MR, Case J, Murphy MP, Ziegler MA, Dinauer MC, Yoder MC, Haneline LS, Dalsing MC, Miller SJ, Labarrere CA, Ingram DA, Unthank JL. Suppressed hindlimb perfusion in Rac2–/– and Nox2–/– mice does not result from impaired collateral growth. Am J Physiol Heart Circ Physiol 2009;296: H877-H886.
  5. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Murphy MP, M. Reza Saadatzadeh MR, Johnstone BH, Ingram DA, March KL. Robust Functional Vascular Network Formation In Vivo by Cooperation of Adipose Progenitor and Endothelial Cells. Circ Res 2009;104:1410-1420.
  6. Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, Min WP, Woods EJ, Reid M, Mansilla E, Marin GH, Drago H, Murphy MP, Minev B. Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med. 2009 Feb 20;7:15.
  7. Eitel JA, Bijangi-Vishehsaraei K, Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE, Mayo LD. PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle. 2009 Mar 15; 8(6):896-901.
  8. Estes ML, Mund JA, Mead LE, Prater DN, Cai S, Wang H, Pollok KE, Murphy MP, An CS, Srour EF, Ingram DA, Case J. Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential. Cytometry.
  9. Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez JP, Harman RJ, Patel AN, Murphy MP, Lee RR, Minev B. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med. 2009 Apr 24;7:29. Review.
  10. Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA, Minev B, Patel AN, Murphy MP, Smith L, Alexandrescu DT, Ichim TE, Riordan NH. Circulating endothelial progenitor cells: a new approach to anti-aging medicine. J Transl Med. 2009 Dec 15;7:106. Review.
  11. Ichim TE, Solano F, Lara F, Rodriguez JP, Cristea O, Minev B, Ramos F, Woods EJ, Murphy MP, Alexandrescu DT, Patel AN, Riordan NH. Combination stem cell therapy for heart failure. Int Arch Med. 2010 Apr 14;3(1):5.
  12. Ziegler MA, Distasi MR, Bills RG, Miller SJ, Alloosh M, Murphy MP, George Akingba A, Sturek M, Dalsing MC, Unthank JL.Marvels, mysteries, and misconceptions of vascular compensation to peripheral artery occlusion. Microcirculation. 2010 Jan;17(1):3-20. Review.
  13. Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA, Minev B, Patel AN, Murphy MP, Smith L, Ramos F, Ichim TE, Riordan NH. Nutraceutical augmentation of  circulating endothelial progenitor cells and hemaotopietic stem cells in human subjects. J Transl Med. 2010 Apr 8; 8:34.
  14. Bijangi-Vishehsaraei K*, Saadatzadeh M.R.*, Huang S, Murphy MP, and Safa AR. 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol Cell Biochem 2010.
  15. Murphy MP, Dalsing MC, Lawson JH, Shafique SS, Klein JH, McKale JM, Abonour RF,Hutchins GD, March KL. Autologous Bone Marrow Mononuclear Cell Therapy is Safe and Promotes Amputation Free Survival in Patients with Critical Limb Ischemia J Vasc Surg 2011;53:1565-74.
  16. Matos J, Fajardo A, Rapp BM, Dalsing MC, Motaganahalli RL, Akingba GA, Lemmon GW, Murphy MP. Evidence for Non-operative Management of Acute Limb Ischemia in the Infant. J Vasc Surg. 2011;55:1156-59.
  17. Rapp BM, Saadatzadeh RM, Tempel,ZS , Bhasvar J, Ofstein RH, Morone PM, Traktuev DO, Grimes B, March KL, Murphy MP.  Resident Endothelial Progenitor Cells from Human Placenta Have Greater Vasculogenic Potential than Circulating Endothelial Progenitor Cells from Umbilical Cord Blood.Cell Transplantation. 2011.
  18. Jester AL, Motaganahalli RL, Rapp BM, Akingba GA, Dalsing MC, Wilson MG, Fajardo A, Murphy MP. Autologous Bone Marrow Mononuclear Cell Therapy Produces Durable Benefits in Limb Salvage at Five Years Post-Treatment  J Vasc Surg 2011;54: 1542-45.
  19. Motaganahalli RL, Murphy MP, Sawchuck AP, Lemmon GL, Fajardo A, Akingba GA, Feliciano B, Cikrit DC, Richardson CR, Dalsing MC. Door To Treatment Time - Identifying Opportunities for Process Improvement: Results From an Institution Based Protocol Caring for Patients with Ruptured Aortic Aneurysms. J Vasc Surg, 2011; 53, 5S-6S.
  20. Rodriguez JP, Murphy MP, Hong S, Madrigal M, March KL, Minev B, Harman RJ, Chen CS, Timmons RB, Marleau AM, Riordan NH. Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. Int Arch Med .2012 Feb 8; 5:5. doi: 10.1186/1755-7682-5-5.
  21. Sharma AK, Lu G, Jester A, Johnston W, Zhao Y, Hajzus V, Saadatzadeh MR, Su G, Bhamidipati CM, Mehta G, Kron IL, Laubach VE, Murphy MP, and Upchurch GR. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 2012;126: S38-S45.
  22. Mizer JC, Ichim TE, Alexandrescu DT, Dasanu CA, Ramos F, Turner A, Woods EJ, Bogin V, Murphy MP, Koos D, Patel AN. Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med. 2012 Nov 21;10 (1):231.
  23. Perin EC, Willerson JT, Pepine CJ, Murphy MP, et al.. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation 2012 000779R1.

Department of Surgery | 545 Barnhill Drive, Emerson Hall 203, Indianapolis, In 46202 | Phone: (317) 274-5771